Ab Science

6 trials Commercial sponsor

Filter these 6 trials by condition, phase, country and more.

Open in Search →

6 Registered trials

0 Recruiting

0 Completed trials

10 Countries active

5 Unique IMPs

N/A Results reported

Phase III

Phase II

Phase I (FiH)

Phase III: 4 Phase II: 1 Phase I (FiH): 1

Oversight events:

18 temporary halts 7 corrective measures across 6 trials

View oversight register →

Top indications

Amyotrophic lateral sclerosis 1

Top IMPs

MASITINIB 5 1-{4-[2-(5-ETHOXYMETHYL-2-METHYL-PHENYLAMINO)-OXAZOL-5-YL]-PHENYL}-IMIDAZOLIDIN-2-ONE 1 AZACITIDINE 1 RILUZOLE 1 VENETOCLAX 1

All trials

6 total

A 24-week with possible extension, prospective, multicenter, randomized, double blind, placebo-controlled, 2-parallel group with a randomiza… Halted

2024-514538-19-00 Phase III 3 countries MASITINIB
A Phase 1/2 Study to Assess the Safety, Pharmacokinetics, and Efficacy of Daily Intravenous of AB8939 in patients with Relapsed/Refractory A… Halted

2024-516641-39-00 Phase I (FiH) 4 countries 1-{4-[2-(5-ETHOXYMETHYL-2-METHYL-PHENYLAMINO)-OXAZOL-5-YL]-PHENYL}-IMIDAZOLIDIN-…
A 24-week, multicenter, randomized, double blind, placebo-controlled, dose-range finding phase II study to compare efficacy and safety of or… Halted

2024-515193-27-00 Phase II 1 country MASITINIB
A 96-Week, Prospective, Multicenter, Randomised, Double-Blind, Placebo-Controlled, Phase 3 Study to Compare Efficacy and Safety of Masitinib… Halted

2024-516672-16-00 Phase III 4 countries MASITINIB
A prospective, multicenter, randomised, double-blind, placebo-controlled, parallel groups, phase 3 study to compare the efficacy and safety … Halted

2024-516671-33-00 Phase III 5 countries MASITINIB
A prospective, multicenter, randomised, double-blind, placebo-controlled, parallel groups, phase 3 Trial to compare the efficacy and safety … Suspended

2024-511244-12-01 Phase III 7 countries MASITINIB; RILUZOLE

Showing 1–6 of 6 trials

← All sponsors A–Z